A new cohort study adds to a now-consistent finding: people taking semaglutide or tirzepatide are diagnosed with non-scarring hair loss more often than matched non-users. This is not a fringe signal — hair loss is printed on the Wegovy label, among the adverse reactions occurring in at least 2% of treated patients and more often than on placebo. The useful questions are how often, and what is driving it. On the second, the evidence points away from the drug itself and toward the weight loss.
What the numbers say
Start with the label, because it is the most rigorous data available. Across the three randomised, double-blind, placebo-controlled trials supporting Wegovy 2.4 mg — 2,116 patients on drug, 1,261 on placebo, up to 68 weeks — hair loss was reported by 3% on semaglutide and 1% on placebo. That is roughly two extra cases per hundred people treated for a little over a year.
A systematic review and meta-analysis published in Skin Appendage Disorders on 30 June 2026 pooled 17 studies covering 1,091,743 patient-exposures. The pooled odds ratio for any non-scarring alopecia was 1.40 (95% CI 1.33–1.48), with no measurable heterogeneity across the three cohort studies contributing to it. By subtype at 12 months: telogen effluvium — the diffuse shedding that follows a physiological shock — had an adjusted odds ratio of 1.76 (1.34–2.32); androgenetic alopecia 1.64 (1.35–1.99); and alopecia areata 1.08 (0.87–1.34), an interval comfortably spanning 1 and therefore showing no association. That last result is doing real work: alopecia areata is autoimmune, and a null there is what you would expect if the mechanism is nutritional rather than immune.
The newest piece, published in The Laryngoscope on 26 August 2026, is a propensity-score-matched cohort drawn from the TriNetX network, covering adults in care from 2018 to 2025 and matched on demographics, comorbidities and other medications associated with hair loss, with alopecia areata built in as a negative control. It reports higher odds of non-scarring alopecia for both semaglutide and tirzepatide, and higher odds of telogen effluvium, with tirzepatide elevated at every follow-up point.
Why it is probably the weight loss
Both papers land on the same explanation, and the strongest evidence for it is almost incidental. In the TriNetX cohort, follow-up BMI was lower in the GLP-1 users who developed hair loss than in those who did not. That is the signature of telogen effluvium: rapid weight loss, and the caloric and micronutrient deficit that comes with it, push follicles into a resting phase, and the shedding surfaces two to three months later. The meta-analysis reaches the same conclusion, attributing the effect primarily to weight-loss-induced micronutrient deficiency; its authors’ advice is to counsel patients before it happens, attend to nutrition, and not stop the drug prematurely.
Two things about the size of it. Odds ratios describe relative change, and on a baseline of 1–3% an odds ratio of 1.40 is a small absolute increase. And telogen effluvium is by definition self-limiting — a shedding phase, not permanent loss. The androgenetic alopecia signal is the more interesting one, because that is not self-limiting, and neither paper explains why an odds ratio of 1.64 turns up there.
What is not yet known: the Laryngoscope abstract states its directions without publishing odds ratios, confidence intervals or cohort sizes, and we could not access the full text — so the magnitude of the newest study is, to us, unverified. TriNetX draws on electronic health records, which capture only the hair loss a patient raised with a clinician and a clinician coded — certainly a fraction of the real total, and plausibly a skewed one. The pharmacovigilance signals in the meta-analysis (reporting odds ratios of 2.46 for semaglutide and 1.73 for tirzepatide) come from spontaneous adverse-event reports, which climb with public attention and so measure reporting at least as much as incidence. And the micronutrient mechanism is inferred from the pattern of results rather than tested: no trial has shown that correcting a named deficiency changes the outcome, which is worth holding onto before buying any of the supplements marketed for it.
Sources: Wegovy (semaglutide) prescribing information, Table 3, Adverse Reactions; DailyMed, label updated 18 June 2026 · Viquez Burboa GU, Flores Guillén MAR, Duardo González VS. “GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.” Skin Appendage Disorders, 30 June 2026, doi:10.1159/000553070 · Katragadda R, et al. “Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.” The Laryngoscope, 26 August 2026, doi:10.1002/lary.70810
